Aurobindo Pharma shares fall 3% after Q2 earnings

New Delhi: Shares of Aurobindo Pharma Tuesday fell almost 3 per cent after the company reported 21.70 per cent dip in consolidated net profit for the quarter ended September 30, 2018. The stock went down 2.96 per cent to end at Rs 774.70 on BSE. During the day, it declined 4.76 per cent to Rs 760.25.

On NSE, shares of the company dropped 2.63 per cent to close at Rs 775.

Aurobindo Pharma Monday reported 21.70 per cent dip in consolidated net profit to Rs 611.44 crore for the September quarter, mainly on account of rise in expenses.

The company had posted a net profit of Rs 780.97 crore in the year-ago period, Aurobindo Pharma said in a BSE filing.

Consolidated total revenue from operations stood at Rs 4,751.40 crore for the quarter under review. It was Rs 4,435.89 crore in the same period last year.

Total expenses stood at Rs 3,964.20 crore for the reported quarter. It was Rs 3,468.36 crore during the same period of 2017-18.

  • Related Posts

    Diabetic drug metformin found to act on brain

    NEW DELHI:  Cheap, effective and widely trusted, metformin has long been the first choice for treating type 2 diabetes. Now, scientists say the drug works in a way few had…

    Hetero debuts semaglutide generic in emerging markets

    New Delhi: Hyderabad-based drugmaker Hetero has announced the launch of its generic semaglutide portfolio in emerging international markets. In a phased global push, the company plans to roll out its…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Diabetic drug metformin found to act on brain

    Diabetic drug metformin found to act on brain

    Hetero debuts semaglutide generic in emerging markets

    Hetero debuts semaglutide generic in emerging markets

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework